Compare CVX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVX | ABBV |
|---|---|---|
| Founded | 1879 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.8B | 358.5B |
| IPO Year | 1994 | 2012 |
| Metric | CVX | ABBV |
|---|---|---|
| Price | $178.12 | $254.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 18 |
| Target Price | $191.80 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 7.0M | 4.8M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.70% | 3.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.11 | 0.39 |
| Revenue | ★ $189,031,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | $18.01 | $11.87 |
| Revenue Next Year | N/A | $8.12 |
| P/E Ratio | ★ $156.95 | $654.15 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $146.49 | $184.63 |
| 52 Week High | $214.71 | $261.64 |
| Indicator | CVX | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 68.54 |
| Support Level | $147.71 | $218.28 |
| Resistance Level | $193.41 | N/A |
| Average True Range (ATR) | 3.08 | 6.69 |
| MACD | 0.57 | 1.40 |
| Stochastic Oscillator | 88.43 | 85.05 |
Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with 2025 worldwide net oil-equivalent production of 3.7 million barrels per day, including 8.5 billion cubic feet per day of natural gas and 2.3 million barrels of liquids per day. Production takes place in North America, South America, Europe, Africa, Asia, and Australia. The company's refining networks arelocated in the United States and Asia, with a total worldwide refining capacity of 1.8 million barrels of oil a day at year-end 2025. Net proved reserves at year-end 2025 stood at 10.6 billion barrels of oil equivalent, consisting of 5.7 billion barrels of liquids and 29.2 trillion cubic feet of natural gas.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.